Serum dehydroepiandrosterone sulfate concentration as an indicator of adrenocortical suppression during inhaled steroid therapy in adult asthmatic patients

Abstract

Objective: Supraphysiological doses of exogenous glucocorticosteroids cause adrenocortical suppression. Dehydroepiandrosterone sulfate (DHEA-S) is the most abundant adrenal androgen and estrogen precursor. We studied to what extent inhaled glucocorticosteroid therapy for asthma decreases serum DHEA-S concentrations. Design and methods: We measured serum DHEA-S and cortisol concentrations in 101 adult patients with newly detected mild asthma before and after 2 and 12 weeks of treatment with inhaled glucocorticosteroids. The patients were randomized to receive budesonide 200 mg/day (low dose group, n ¼ 50) or 800 mg/day (high dose group, n ¼ 51) in two parallel groups double-blindly. Results: In the low dose group, serum DHEA-S concentrations decreased from the baseline by a mean of 8 % (95 % confidence interval (CI), 3-13 %, P , 0.01) after 2 weeks of therapy, and by 2 % (95 % CI, 9 % decrease to 5 % increase, NS) after 12 weeks. In the high dose group, the respective decreases were 16 % (95 % CI, 10-21 %, P , 0.001) and 18 % (95 % CI, 12 -24 %, P , 0.001). The difference between the treatment groups was significant at both 2 and 12 weeks. During the 12 week treatment period the baseline concentrations of serum cortisol did not decrease in the low dose group, while in the high dose group the decrease was significant at 12 weeks (P , 0.01), but not at 2 weeks. The forced expiratory volume in 1 s improved equally well in both groups. Conclusions: Inhaled budesonide decreased serum DHEA-S concentrations, which may indicate adrenocortical suppression. Reduced adrenal production of androgen and estrogen precursors may increase the risk of osteoporosis especially in postmenopausal women.European Journal of Endocrinology 150 687-690

Metabolomics analysis identifies different metabotypes of asthma severity

“…ICS are considered to be relatively safe at low-moderate doses [42]; our findings did indeed indicate that higher doses (and oral treatment) are associated with the most pronounced metabolic effects. Reduced levels of DHEA-S, cortisone and cortisol reflect hypothalamus–pituitary–adrenal axis suppression, a well-documented consequence of high-dose ICS treatment [42, 43]. C omhair et al.…”

Screening for hypothalamic–pituitary–adrenal axis suppression in asthmatic children remains problematic: a cross-sectional study

“…Serum DHEAS has repeatedly been touted in the literature as a useful screening tool for central AI18 19 or for HPAS in asthmatics treated with ICS 6 7 20–22. In one study, it was claimed that the serum DHEAS is a ‘practical surrogate measurement’ to identify asthmatic children at risk of HPAS 6.…”

Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS)

“…In another related situation, medically ill patients treated with glucocorticoid medications (e.g., prednisone, dexamethasone) develop hypothalamic-pituitary-adrenal (HPA) axis inhibition [144]. While this HPA inhibition is salutary in the case of cortisol, since the exogenous glucocorticoid medication occupies the glucocorticoid receptors, it may be disadvantageous in the case of DHEA(S) whose actions are not mimicked by the glucocorticoid medication [98; 185].…”